Abstract: A use of (S)-(?)-?-ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment of particular disease and new pharmaceutical compositions comprising (S)-(?)-?-ethyl-2-oxo-1-pyrrolidineacetamide.

Abstract: The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obsructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.

Abstract: There is described a polymer film preferably selected from polyolefin, polyester, polyamide, acrylic, polystyrene, or polyurethane, where the film is coated with an ink-jet printable ink receiving layer which when ink-jet printed has an average percent increase in droplet size on the ink receiving layer of less than about 5% between about 0.2 and about 2.0 sec after printing.

Abstract: A method for bonding DVD layers which comprises EB bonding at least two layers of a DVD with an EB curable adhesive composition which consists essentially of at least one epoxy resin and at least one aryl iodonium salt (cationic) photoinitiator and DVDs produced by this method.

Abstract: A substantially reactive and gel-free composition which comprises: a. particles capable of reaction with a radiation curable resin; b. a coupling agent for modification of the surface of said particles; c. a radiation curable resin; d. a radiation curable salt capable of inhibiting gel formation in said composition.

Abstract: This invention relates to the combination of muscarinic agonists with narcotic analgesics, non-steroidal anti-inflammatory drugs or other analgesic drugs and to their use as antinociception (pain relief) agents. In particular, the invention relates to a combination of a specific class of M4 selective muscarinic agonists with narcotic analgesics, non-steroidal anti-inflammatory drugs or other analgesic drugs.

Abstract: The invention relates to a water based polymer composition comprising a biopolymer and a synthetic polymer resin. The biopolymer results from a mechanical thermoplastic processing of a polysaccharide and/or protein starting material using shear forces in the presence of a crosslinking agent. The synthetic polymer resin consists of a water based hydrophilic resin and/or hydrophilic/hydrophobic resin. These compositions have a good storage stability. They are intended for the production of coatings with fair properties.

Abstract: A method is described for preparing a fluid pharmaceutical composition which allows the controlled release of at least one active substance. The method involves mixing a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to 72% by weight of pharmaceutically acceptable solvent, and from 4 to 52% by weight of fatty acid. The composition has a property of gelling instantaneously in the presence of an aqueous phase.

Abstract: The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.

Abstract: The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.

Abstract: Powder compositions hardenable by radiation usable for preparing paints or varnishes, specific amorphous polyesters which are comprised within these powder compositions, the use of the paints or varnishes comprising the powder compositions for coating an article as well as articles coated with the hardened paints or varnishes are disclosed. The powder compositions of the invention are especially suited for coating over metal and heat-sensitive substrates and combine, upon melting at low temperatures and curing by radiation, a series of properties such as good flow and film hardness along with an outstanding solvent resistance.

Abstract: The invention concerns 2-oxo-1-pyrrolidine derivatives of formula (I) wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.

Abstract: The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.

Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam SV2 proteins, including SV2A.

Abstract: The present invention provides pharmaceutical compositions and novel compounds useful in the treatment of conditions mediated by CCR2, MCP-1 or the interaction thereof. The compounds of the present invention are pyrrolidinones and pyrrolidine-thiones.

Abstract: The invention concerns powder thermosetting coating compositions comprising (a) an amorphous polyester containing carboxyl groups, rich in isophthalic acid and neopentylglycol, optionally branched with a polycarboxylic acid or a polyol containing at least three functional groups; (b) a semicrystalline polyester containing carboxyl groups prepared from one or several saturated aliphatic dicarboxylic acids with linear chain, and from a saturated aliphatic diol with linear or cyclic chain optionally branched with a polycarboxylic acid or with a polyol containing at least three functional groups, and having a melting point (Tm) of at least 40° C. and an acid value of 5 to 50 mg of KOH/g, and (c) a cross-linking agent. Said compositions are useful for preparing powder paints and varnishes providing excellent quality coatings whereof the brilliance measured at an angle of 60°, according to the ASTM D 523 standard is always less than 50%, that is half-gloss or matt coatings.

Abstract: The invention concerns a polyester bearing tertiary carboxyl groups, characterised in that it consists of: (a) 8.1 to 35 moles of an aliphatic or cycloaliphatic of a polyol; (b) 9.1 to 36 moles of an aliphatic, cycloaliphatic or aromatic polycarboxylic acid; (c) 1.6 to 2.8 moles of an aliphatic, cycloaliphatic or aromatic compound comprising a tertiary carboxyl group and either a primary or secondary carboxyl group, or a primary or secondary hydroxyl group. Said polyester is prepared in several steps, the first steps consisting in the preparation of a polyester by condensation between (a) an aliphatic or cycloaliphatic polyol, and (b) an aliphatic, cycloaliphatic or aromatic polycarboxylic acid, the final step consisting in condensing said polyester with (c) an aliphatic, cycloaliphatic or aromatic compound comprising a tertiary carboxyl group and either a primary or secondary carboxyl group, or a primary or secondary hydroxyl group.

Abstract: The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.

Abstract: The present invention is directed a pharmaceutical composition which can be administered orally, allowing for the controlled release of at least one active substance. The composition includes at least one active substance, between 5 and 60% by weight, relative to the total weight of the composition, of at least one excipient, selected from inert matrices, hydrophilic matrices, lipid matrices, mixtures of inert matrices and of lipid matrices, and mixtures of hydrophilic matrices and of inert matrices, with the exception of mixtures including a polyacrylic acid and at least one hydrophilic matrix of the cellulose type; and between 5 and 50% by weight, relative to the total weight of the composition, of at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions, selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates, phosphates, sodium borate and basic salts of organic acids.

Abstract: The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.